

mspharma

RECONSTITUTION OF BORVIX® (BORTEZOMIB) 3.5 MG POWDER FOR SOLUTION FOR INJECTION

Objective

The educational material is essential to ensure the safe and effective use of the product and appropriate management of the Medication error.

For subcutaneous (SC) or intravenous (IV) administration

SUBCUTANEOUS ADMINISTRATION

TO

reconstitute add 1.4 mL
of sterile 0.9% sodium chloride
solution into the vial of Bortezomib for
a final concentration of
2.5 mg/mL

INTRAVENOUS ADMINISTRATION

TO

reconstitute add 3.5 mL
of sterile 0.9% sodium chloride
solution into the vial of Bortezomib for
a final concentration of
1.0 mg/mL

- The volume of diluent used to reconstitute Bortezomib for SC administration is different from the volume for IV administration.
- Due to the different volume added, the solutions after reconstitution differ in drug concentration.
- Bortezomib must be reconstituted by a Health Care Professional using a syringe of the appropriate size, without removing the vial stopper and utilising strict aseptic techniques since no preservative is present.
- The reconstituted product should be used immediately after preparation.
- To avoid administration errors, syringes for SC and IV use should be labelled differently.

Subcutaneous or Intravenous use only. Do not give by other routes.

- Please report any adverse event experienced with the administration of Bortezomib immediately.
- Please refer to Summary of Product Characteristics (SmPC) for further instructions.

Reporting of Side effects

Please report any suspected adverse drug reactions associated Borvix® (Bortezomib) to:

• Local representative at MS Pharma Saudi

- Email: pharmacovigilance@mspharma.com
- Website: www.mspharma.com
- Phone No: + 966112790122 Ext. 6013

• The National Pharmacovigilance Centre (NPC) Saudi Food and Drug Authority (SFDA)

- Email: npc.drug@sfd.gov.sa
- Call Center: 19999
- Website: <https://ade.sfda.gov.sa/>
- QR Code:



1. Borvix® (Bortezomib) SmPC and leaflet.

2. Reconstitution Poster - Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content). (2019). Retrieved 9 July 2020, from <https://www.medicines.org.uk/emc/rmm/1428/Document>